{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T23:09:07Z","timestamp":1773356947964,"version":"3.50.1"},"reference-count":16,"publisher":"Japanese Society for the Study of Xenobiotics","issue":"2","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2008]]},"DOI":"10.2133\/dmpk.23.115","type":"journal-article","created":{"date-parts":[[2008,4,30]],"date-time":"2008-04-30T05:52:02Z","timestamp":1209534722000},"page":"115-119","source":"Crossref","is-referenced-by-count":20,"title":["The Effect of Bucolome, a CYP2C9 Inhibitor, on the Pharmacokinetics of Losartan"],"prefix":"10.2133","volume":"23","author":[{"given":"Mariko","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"900","reference":[{"key":"10.2133\/dmpk.23.115_bb0005","first-page":"205","article-title":"Angiotensin II receptors and angiotensin II receptor antagonists","volume":"45","author":"Timmermans","year":"1993","journal-title":"Pharmacol Rev"},{"key":"10.2133\/dmpk.23.115_bb0010","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0009-9236(95)90020-9","article-title":"Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans","volume":"58","author":"Lo","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.2133\/dmpk.23.115_bb0015","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0009-9236(98)90163-1","article-title":"Effect of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers","volume":"63","author":"Williamson","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.2133\/dmpk.23.115_bb0020","first-page":"105","article-title":"The role of CYP2C9 polymorphism in losartan oxidation","volume":"29","author":"Yasar","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.2133\/dmpk.23.115_bb0025","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1172\/JCI109722","article-title":"Stereoselective interaction of phenylbutazone with [12C\/13C] warfarin pseudoracemates in man","volume":"65","author":"O'Reilly","year":"1980","journal-title":"J Clin Invest"},{"key":"10.2133\/dmpk.23.115_bb0030","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1161\/01.CIR.65.1.202","article-title":"Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man","volume":"65","author":"O'Reilly","year":"1982","journal-title":"Circulation"},{"key":"10.2133\/dmpk.23.115_bb0035","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/00912700122010186","article-title":"The stereoselective effects of bucolome on the pharmacokinetics and pharmacodynamics of racemic warfarin","volume":"41","author":"Matsumoto","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.2133\/dmpk.23.115_bb0040","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0731-7085(96)01948-6","article-title":"An improved method for the simultaneous determination of losartan and its major metabolite, E3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection","volume":"15","author":"Ritter","year":"1997","journal-title":"J Pharm Biomed Anal"},{"key":"10.2133\/dmpk.23.115_bb0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0021-9673(01)01496-0","article-title":"Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection","volume":"949","author":"Gonzalez","year":"2002","journal-title":"J Chromatogy A"},{"key":"10.2133\/dmpk.23.115_bb0050","first-page":"1628","article-title":"Merck & Co. Cozaar tablets. In: Physicians' Desk Reference. 50th ed","volume":"1996","author":"Oradell","year":"1996","journal-title":"Medical Economics Company"},{"key":"10.2133\/dmpk.23.115_bb0055","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.1992.56","article-title":"Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist","volume":"51","author":"Munafo","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.2133\/dmpk.23.115_bb0060","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2125.1993.tb05696.x","article-title":"Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans","volume":"35","author":"Ohtawa","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"10.2133\/dmpk.23.115_bb0065","first-page":"1160","article-title":"Synthesis and identification of a novel tetrazole metabolite of the angiotensin II receptor antagonist DuP 753","volume":"19","author":"Stearns","year":"1991","journal-title":"Drug Metabo Dispos"},{"key":"10.2133\/dmpk.23.115_bb0070","first-page":"281","article-title":"The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices","volume":"20","author":"Stearns","year":"1992","journal-title":"Drug Metabo Dispos"},{"key":"10.2133\/dmpk.23.115_bb0075","first-page":"223","article-title":"Metabolic fate of losartan, a new angiotensin II receptor antagonist (1): absorption, distribution, metabolism and excretion after single administration in rats","volume":"10","author":"Takayama","year":"1995","journal-title":"Xenobio Metabol Dispos"},{"key":"10.2133\/dmpk.23.115_bb0080","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1046\/j.1365-2125.2000.00134.x","article-title":"Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions","volume":"49","author":"Ohyama","year":"2000","journal-title":"Br J Clin Pharmacol"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715301671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715301671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T21:22:53Z","timestamp":1557523373000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715301671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"alternative-id":["S1347436715301671"],"URL":"https:\/\/doi.org\/10.2133\/dmpk.23.115","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2008]]}}}